

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Boylan et al.

Serial No: 09/909,474

Filed: July 19, 2001


**Title: Novel Serine-Threonine Kinase  
Member, h2520-59**

Group Art Unit: 1652

Examiner: Maryam Monshipouri

I hereby certify that this paper and the petition and fee referred to as being filed herewith are being deposited with the United States Postal Service with sufficient postage as first class mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450:

Date: July 6, 2004

  
Lynn L. Janulis, Ph.D.  
Registration No. 53,066  
Agent for Applicants

## AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

This amendment is being filed in response to the non-final Office Action mailed February 5, 2004 (hereafter, the "Office Action"). Claims 1-5, 8, 10-11, 53-55, 68-69, and 75-76 are currently under examination and were variously rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement and for lack of written description, under § 112, second paragraph, and under § 102(a) over either U.S. Patent No. 6,387,676 (Virca et al.) or US2002/0197679, published December 26, 2002 (Tang et al.). Reconsideration and withdrawal of the rejections are respectfully requested in light of the following amendment and remarks. This response is timely filed along with a petition for a two-month extension of time.

**Amendments to the claims** begin at page 2 of this paper.

**Remarks begin at page 11 of this paper.**